Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CEMPRA, INC. (MLNT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/08/2018 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"FORM 8-K/A",
"Amended and Restated License Agreement, between Melinta Therapeutics, Inc. and Wakunaga Pharmaceutical Co. Ltd",
"License and Supply Agreement, by and between Melinta Therapeutics, Inc. and Cydex Pharmaceuticals, Inc. (a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated), incorporated by reference to 9 of the S-1/A filed by Rib-X Pharmaceuticals, Inc. on March 13, 2012" |
|
| 01/10/2018 |
8-K/A
| Financial Statements and Exhibits |
| 12/06/2017 |
8-K/A
| Financial Statements and Exhibits |
| 12/05/2017 |
8-K/A
| Entered into an underwriting agreement for the issuance and sale of notes|
Docs:
|
"Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm",
"Audited Consolidated Financial Statements as of December 31, 2016 and 2015, and for the Years Ended December 31, 2016, 2015, and 2014",
"Unaudited Condensed Consolidated Financial Statements as of September 30, 2017 and for the Three- and Nine-Month Periods Ended September 30, 2017 and September 30, 2016",
"Melinta's Management's Discussion and Analysis of Financial Condition and Results of Operations",
"Unaudited Pro Forma Condensed Combined Financial Statements" |
|
| 10/24/2012 |
8-K/A
| Form 8-K/A - Current report [Amend] |
|
|